LEADER 01570nam  2200445Ia 450 
001 9910698870003321
005 20090511160404.0
035   $a(CKB)5470000002397164
035   $a(OCoLC)320778975
035   $a(EXLCZ)995470000002397164
100   $a20090511d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eminimally manipulated, unrelated, allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution in patients with hematological malignancies
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2006]
215   $aii, 46 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 11, 2009).
300   $a"Draft guidance."
300   $a"December 2006".
320   $aIncludes bibliographical references (page 46).
517   $aGuidance for industry 
606   $aFetal blood
606   $aHematopoiesis
606   $aHematoma
606   $aBlood banks$xLicenses$zUnited States
615  0$aFetal blood.
615  0$aHematopoiesis.
615  0$aHematoma.
615  0$aBlood banks$xLicenses
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698870003321
996   $aGuidance for industry$93434577
997   $aUNINA